Buehning, Florian
Lerchner, Tobias
Vogel, Julia
Hendgen-Cotta, Ulrike B.
Totzeck, Matthias
Rassaf, Tienush
Michel, Lars
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (RA 969/12-1, HE 6317/2-1)
Medical Faculty, University Duisburg-Essen (IFORES scholarship)
Universitätsklinikum Essen
Article History
Received: 5 March 2024
Revised: 30 June 2024
Accepted: 16 July 2024
First Online: 22 July 2024
Declarations
:
: F.B. and T.L. have no competing interests to declare that are relevant to the content of this article. M.T. reports personal fees and others from Edwards, Novartis, Bristol Myers Squibb, Bayer, Daiichi Sankyo und AstraZeneca and Pfizer outside of the submitted work. J.V. reports personal fees from Eli Lilly outside of the submitted work. T.R. reports personal fees and others from Edwards, Novartis, Bristol Myers Squibb, Bayer, Daiichi Sankyo und AstraZeneca and Pfizer outside of the submitted work. T.R. is a co-founder of Bimyo, a company focusing on the development of cardioprotective peptides. U.B.H.-C. is a co-founder of Bimyo, a company focusing on the development of cardioprotective peptides. L.M. reports personal fees from Bayer, Alnylam, AstraZeneca, Bristol Myers Squibb, Pfizer, IFFM e.V. and from Bund der Niedergelassenen Kardiologen (BNK) outside of the submitted work.
: This review article is based on existing literature and does not involve any original human or animal data. As such, ethical approval and informed consent are not applicable.